StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Down 3.4 %

Shares of EVGN stock opened at $1.41 on Friday. The company has a market capitalization of $7.56 million, a P/E ratio of -0.32 and a beta of 1.29. Evogene has a 12-month low of $1.20 and a 12-month high of $10.40. The firm has a 50-day moving average price of $1.59 and a 200 day moving average price of $2.13.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.